ARTL 주가 차트
ARTL 수입
Artelo Biosciences Inc
$3.57
-5.3%
$-0.2
종가: Apr 28, 16:00:00 GMT-4
$3.55
-0.56%
$-0.02
애프터마켓: Apr 28, 20:00:00 GMT-4
뒤로
Artelo Biosciences Inc (ARTL) 수입
최신 수익 결과: Q4 '25
보고됨: 2026-02-24
역사적 수익
분기별
연간
EPS
수익
Earnings FAQ
ARTL의 최근 주당순이익(EPS)은 예상과 비교하여 어떤가요?
Artelo Biosciences Inc ARTL의 지난 분기 매출 실적은 어땠나요?
Artelo Biosciences Inc의 매출 추정치는 얼마인가요?
Artelo Biosciences Inc의 수익 품질 점수는 얼마인가요?
Artelo Biosciences Inc는 언제 수익을 보고하나요?
Artelo Biosciences Inc의 예상 수익은 얼마인가요?
Artelo Biosciences Inc은 수익 기대치를 충족했나요?
주요 통계
이전 종가
$3.77
시가
$3.66
일일 범위
$3.37 - $3.71
52주 범위
$2.95 - $85.8
거래량
686.0K
평균 거래량
2.8M
배당수익률
--
EPS(TTM)
-39.25
시가총액
$2.8M
ARTL란 무엇인가요?
Artelo Biosciences Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in Solana Beach, California and currently employs 7 full-time employees. The company went IPO on 2015-10-13. Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company dedicated to the development and commercialization of therapeutics that modulate lipid-signaling pathways. The firm is advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation. Its pipeline products include ART26.12, ART27.13 and ART12.11. ART26.12, its Fatty Acid Binding Protein 5 (FABP5) inhibitor, is being developed as a novel, peripherally acting, non-opioid, non-steroidal analgesic. The Cancer Appetite Recovery Study (CAReS) is a Phase 1/2 randomized, placebo-controlled trial of its clinical program, ART27.13, in patients with cancer anorexia and weight loss. ART12.11, the Company's novel solid-state cannabidiol composition co-formed with tetramethylpyrazine, is targeted for development in anxiety disorders and rare/orphan diseases.